The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

  • J. P. Sullivan
  • K. F. Tipton
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 29)


The interactions of a number of derivatives of the dopaminergic neurotoxin MPTP (l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with monoamine oxidase (MAO) have been studied. The desmethyl derivative, 4-phenyl-1,2,3,6-tetrahydropyridine (PTP), was oxidised by MAO-B to form the corresponding dihydropyridine. Initial interaction with both forms of MAO was competitive. However the degree of inhibition of MAO-B, but not MAO-A, increased with time and became irreversible. Substitution of a methyl group at the 6-position of the heterocyclic ring of MPTP prevented it from acting as a substrate for MAO-B and greatly decreased its potency as an inhibitor of that form of MAO, although it remained a good competitive inhibitor of MAO-A. Replacement of the tetrahydropyridine ring of PTP by piperidine apparently abolished the ability to act as a substrate for MAO-B. The compound was however a competitive inhibitor of both forms of MAO. Substitution of a 3-(chlorophenyl)-methoxy-group at the 4’-position of this compound and PTP led to compounds which appeared to be devoid of substrate activity although they were potent, highly-selective, time-dependent inhibitors of MAO-B.


Monoamine Oxidase Irreversible Inhibitor Dihydropyridine Derivative Tetrahydropyridine Ring Brain Monoamine Oxidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abell CW, Fritz RR, Patel NT, Shen RS, Gessner W, Brossi A (1986) Effects of MPTP and its metabolites on neurotransmitter degrading enzymes. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ (eds) MPTP: a neurotoxin producing a Parkinsonian syndrome. Academic Press, New York, pp 219–233.Google Scholar
  2. Arai Y, Kinemuchi H, Hamamichi N, Satoh N, Tadano T, Kisara K (1986) Inhibition of rat brain monoamine oxidase by some analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine and 1-methyl-4-phenylpyridinium ion. Neurosci Lett 66: 43–48.PubMedCrossRefGoogle Scholar
  3. Bradbury AJ, Costall B, Domeney AM, Jenner P, Marsden CD, Naylor RJ, Tan CCW (1985) The neurotoxic actions of MPTP in the rat are not confined to dopamine and the substantia nigra. Br J Pharmacol 86: 691p.Google Scholar
  4. Castagnoli N, Chiba K, Trevor AJ (1985) Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 36: 225–230.PubMedCrossRefGoogle Scholar
  5. Dostert P, Strolin Benedetti M, Tipton KF (1989) Interactions of monoamine oxidase with substrates and inhibitors. Med Res Rev 9: 45–89.PubMedCrossRefGoogle Scholar
  6. Irwin IJ, Langston WL, Delanney LE (1987) 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentration and neurotoxicity. Life Sci 40: 731–740.PubMedCrossRefGoogle Scholar
  7. Javitch JA, D’Amato RJ, Strittmater SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173–2177.PubMedCrossRefGoogle Scholar
  8. Kinemuchi H, Fowler CJ, Tipton KF (1987) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson’s disease. Neurochem Int 11: 359–373.PubMedCrossRefGoogle Scholar
  9. Langston JW, Irwin I, Langston EB, Forno LS (1984) The importance of the 4-5 double bond for neurotoxicoty in primates of the pyridine derivative MPTP. Neurosci Lett 50: 289–294.PubMedCrossRefGoogle Scholar
  10. Mantle TJ, Tipton KF, Garrett NJ (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 25: 2073–2077.PubMedCrossRefGoogle Scholar
  11. Melamed E, Rosenthal J, Cohen O, Globus M, Uzzan A (1985) Dopamine but not nor-epinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur J Pharmacol 116: 179–181.PubMedCrossRefGoogle Scholar
  12. O’Carroll A-M, Fowler CJ, Phillips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiedebergs Arch Pharmacol 322: 198–202.PubMedCrossRefGoogle Scholar
  13. Pileblad E, Carlsson A (1985) Catecholamine uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in mouse brain. Neuropsychophar-macology 24: 689–692.Google Scholar
  14. Salach JI (1979) Monoamine oxidase from beef liver mitochondria: simplified isolation procedure, properties and determination of its cysteinyl flavin content. Arch Biochem Biophys 192: 128–137.PubMedCrossRefGoogle Scholar
  15. Singer TP, Salach JI, Castagnoli N, Trevor A (1986) Interactions of the neurotoxin I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem J 135: 785–789.Google Scholar
  16. Snyder SH, D’Amato RJ (1985) Predicting Parkinson’s disease. Nature 317: 198–199.PubMedCrossRefGoogle Scholar
  17. Sundström E, Jonsson G (1986) Differential time course of protection by monoamine oxidase inhibition and uptake inhibition against MPTP neurotoxicity on central catecholamine neurons in mice. Eur J Pharmacol 122: 275–278.PubMedCrossRefGoogle Scholar
  18. Tipton KF (1985) Determination of monoamine oxidase. Meth Find Exptl Clin Pharmacol 7: 361–367.Google Scholar
  19. Tipton KF, Fowler CJ, McCrodden JM, Strolin Benedetti M (1983) The enzyme-activated ireversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)-methoxy]-phenyl)-5-[(methylamino)methyl]-2-oxazolidinone methane sulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions. Biochem J 209: 235–242.PubMedGoogle Scholar
  20. Tipton KF, McCrodden JM, Youdim MBH (1986) Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem J 125: 521–524.Google Scholar
  21. Trevor AJ, Chiba K, Yu EY, Caldera PS, Castagnoli KP, Castagnoli N, Peterson L, Salach JI, Singer TP (1986) The metabolism of MPTP in vitro. The intermediate role of 2,3-MPDP+ and studies on its chemical and biochemical reactivity. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ (eds) MPTP: a neurotoxin producing a Parkinsonian syndrome. Academic Press, New York, pp 161–172.Google Scholar
  22. Waldmeier PC, Feiner AE, Tipton KF (1983) The monoamine oxidase inhibiting properties of CGP 11305A. Eur J Pharmacol 94: 73–83.PubMedCrossRefGoogle Scholar
  23. Youngster SK, Sonsalla PK, Heikkila RE (1987) Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine. J Neurochem 48: 929–934.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • J. P. Sullivan
    • 1
  • K. F. Tipton
    • 1
    • 2
  1. 1.Department of BiochemistryTrinity CollegeDublinIreland
  2. 2.Department of BiochemistryTrinity CollegeDublin 2Ireland

Personalised recommendations